Organon price target lowered to $22 from $32 at Piper Sandler

Piper Sandler analyst David Amsellem lowered the firm’s price target on Organon to $22 from $32 to reflect certain realities associated with the business, while keeping an Overweight rating on the shares. The absence of exposure to generics, visibility into the stability of the established brands segment, and a growing women’s health footprint all justify an EBITDA multiple that is at a premium to the peer group, the firm says.